Trial Profile
An Open-Label, Single-Centre,Two Part Phase I Mass Balance Study to Assess the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of Orally Administered [14C]-TAK-385 in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2016
Price :
$35
*
At a glance
- Drugs Relugolix (Primary) ; Relugolix (Primary)
- Indications Endometriosis; Prostate cancer; Solid tumours; Uterine leiomyoma
- Focus Pharmacokinetics
- Sponsors Takeda
- 10 Dec 2014 Status changed from not yet recruiting to completed, according to ClinicalTrials.gov record.
- 07 Oct 2014 New trial record